Meta-data analysis as a strategy to evaluate individual and common features of proteomic changes in breast cancer

Cancer Genomics and Proteomics

Volumn 8, Issue 1, 2011, Pages 1-14

  Zakharchenko, Olena ^a   Greenwood, Christina ^b   Lewandowska, Anna ^a,c   Hellman, Ulf ^d   Alldridge, Louise ^b,e   Souchelnytskyi, Serhiy ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^d UPPSALA UNIVERSITY   (Sweden)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

Breast cancer; Meta data analysis; Proteomics; Signalling

Indexed keywords

CASEIN KINASE II; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEOME;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; META ANALYSIS; PROTEOMICS; REGULATORY MECHANISM;

EID: 79951976865     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Weigelt B and Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6: 718-730, 2009.
2. Kataja V and Castiglione M: ESMO Guidelines Working Group: Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(S4): 10-14, 2009.
3. Cardoso F and Castiglione M: ESMO Guidelines Working Group: Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(S4): 15-18, 2009.
4. Moulder S and Hortobagyi GN: Advances in the treatment of breast cancer. Clin Pharmacol Ther 83: 26-36, 2008.
5. Pfeffer U, Romeo F, Noonan DM and Albini A: Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26: 547-558, 2009.
6. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK and Tangrea MA: Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn 9: 455-467, 2009.
7. Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T and Deissler H: Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 14: 3345-3353, 2008.
8. Steinman S, Wang J, Bourne P, Yang Q and Tang P: Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37: 127-134, 2007.
9. Hanash S: Disease proteomics. Nature 422: 226-232, 2003.
10. Hondermarck H, Tastet C, El Yazidi-Belkoura I, Toillon RA and Le Bourhis X: Proteomics of breast cancer: the quest for markers and therapeutic targets. J Proteome Res 7: 1403-1411, 2008.
11. Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol 28: 3366-3379, 2010.
12. Li J, Gromov P, Gromova I, Moreira JM, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L and Celis JE: Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics 8: 5038-5052, 2008.
13. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F and Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 4: 65-89, 2010.
14. Johann DJ, Rodriguez-Canales J, Mukherjee S, Prieto DA, Hanson JC, Emmert-Buck M and Blonder J: Approaching solid tumour heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 8: 2310-2318, 2009.
15. Jia M, Souchelnytskyi N, Hellman U, O'Hare M, Jat P and Souchelnytskyi S: Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is down-regulated in human breast cancer. Proteomics Clin Appl 4: doi: 10.1002/prca.201000006, 2010.
16. + progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol 1: 321-349, 2007. (Pubitemid 350181646)
17. Nimeus E, Malmström J, Johnsson A, Marko-Varga G and Fernö M: Proteomics analysis identifies candidate proteins associated with distant reccurences in breast cancer after adjuvant chemotherapy. J Pharmaceut Biomed Anal 43: 1086-1093, 2007. (Pubitemid 46185804)
18. Metodiev M and Alldridge L: Phosphoproteomics: a possible route to novel biomarkers of breast cancer. Proteomics Clin Appl 2: 181-194, 2008. (Pubitemid 351284899)
19. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB and Hennessy BT: Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15: 3654-3662, 2009.
20. Conrotto P and Souchelnytskyi S: Proteomic approaches in biological and medical sciences: principles and applications. Exp Oncol 30: 171-180, 2008.
21. Weiss W and Görg A: High-resolution two-dimensional electrophoresis. Methods Mol Biol 564: 13-32, 2009.
22. Goodison S and Urquidi V: Breast tumour metastasis: analysis via proteomic profiling. Expert Rev Proteomics 5: 457-467, 2008. (Pubitemid 351871121)
23. Stasyk T, Dubrovska A, Lomnytska M, Yakymovych I, Wernstedt C, Heldin CH, Hellman U and Souchelnytskyi S: Phosphoproteome profiling of transforming growth factor (TGF)-beta signalling: abrogation of TGFbeta1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription. Mol Biol Cell 16: 4765-4780, 2005. (Pubitemid 41416459)
24. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
25. Romieu-Mourez R, Landesman-Bollag E, Seldin DC and Sonenshein GE: Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62: 6770-6778, 2002. (Pubitemid 35364150)
26. Carvalho I, Milanezi F, Martins A, Reis RM and Schmitt F: Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7: R788-795, 2005.
27. Jerry DJ, Dunphy KA and Hagen MJ: Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol Life Sci 67: 1017-1023, 2010.
28. Mazurek S: Pyruvate kinase type M2: a key regulator of the budget metabolic system in tumour cells. Int J Biochem Cell Biol doi:10.1016/j.biocel. 2010.02.005, 2010.
29. Barcellos-Hoff MH and Akhurst RJ: Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 11: 202, 2009.
30. Souchelnytskyi S: Proteomics of TGF-beta signalling and its impact on breast cancer. Expert Rev Prot 2: 925-935, 2005.
31. Lomnytska M, Dubrovska A, Hellman U, Volodko N and Souchelnytskyi S: Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer 118: 412-421, 2006. (Pubitemid 41779081)
32. Kitano H: Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 4: 227-235, 2004.